What Patients are Reading
Last week, researchers released the full results for a trial of empagliflozin (Jardiance), a sodium glucose cotransporter 2 (SGLT2) for treating type 2 diabetes. The results are 'astounding,' but what do they mean?
Visit http://www.medpagetoday.com/Endocrinology/Diabetes/53698 to view the full article online.
|
A typical American turning 65 this year is in line to receive about $500,000 in lifetime Social Security and Medicare benefits. That's more than $1 million for older couples. But many still won't have enough money to pay for out-of-pocket medical care and long-term supports and services.
Visit http://onforb.es/1QvOvZm to view the full article online.
|
|